Nuvation Bio Inc. Class A Common Stock vs Onto Innovation — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Onto Innovation trades at $299.81 (market cap $14.94B). The key difference: Onto Innovation is far larger — about 8.7× Nuvation Bio Inc. Class A Common Stock's market cap, and Onto Innovation is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Onto Innovation for 5 Days on average.
| NUVB | ONTO | |
|---|---|---|
Market Cap | $1.71B | $14.94B |
Volume | 5,448,712 | 933,124 |
Sector | Health | Technology |
52-Week High | $9.54 | $378.45 |
52-Week Low | $3.41 | $121.34 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $1.30B | $14.53B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →